Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Beactica Therapeutics AB
AB
Active
Org 5567082853
Rapsgatan 7, 754 50
Uppsala
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2006 · 19 years old
1-4 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Beactica Therapeutics AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
11M
8M
6M
3M
0M
2021: 4M
4M
2021
2022: 7M (+75% vs 2021)
7M
+75%
2022
2023: 7M (0% vs 2022)
7M
0%
2023
2024: 9M (+29% vs 2023)
9M
+29%
2024
2025: 6M (-33% vs 2024)
6M
-33%
2025
EBITDA
SEK millions
0M
-3M
-6M
-9M
-12M
2021: -10M
-10M
2021
2022: -10M (0% vs 2021)
-10M
0%
2022
2023: -9M (+10% vs 2022)
-9M
+10%
2023
2024: -5M (+44% vs 2023)
-5M
+44%
2024
2025: -7M (-40% vs 2024)
-7M
-40%
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
5 734
8 701
7 385
7 341
4 469
Staff expenses
−4 482
−6 678
—
—
—
EBITDA
−7 288
−4 901
−8 742
−10 340
−9 520
Depreciation & amort.
−46
−46
−180
−203
−536
EBIT
−7 334
−4 947
−8 922
−10 543
−10 056
Net financials
−14
33
−97
−109
−142
Profit before tax
−7 348
−4 914
−9 019
−10 652
−10 199
Tax
—
—
−0
−0
−0
Net profit
−7 348
−4 914
−9 019
−10 652
−10 199
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
35 074
32 175
29 972
36 506
28 343
Equity
32 598
29 813
27 118
31 135
21 699
Long-term debt
186
0
486
1 049
1 798
Short-term debt
2 290
2 362
2 368
4 323
4 846
Total debt
2 476
2 362
2 854
5 372
6 644
Financial ratios
5-year trend
EBITDA margin
−127,1 %
This company
15,8 %
Market median
This company
Market median
904% below market
2021
2025
Equity ratio
92,9 %
This company
38,2 %
Market median
This company
Market median
143% above market
2021
2025
Return on equity
−22,5 %
This company
18,4 %
Market median
This company
Market median
222% below market
2021
2025
Net profit margin
−128,2 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2021
2025
Asset turnover
0,16×
This company
1,12×
Market median
This company
Market median
86% below market
2021
2025
Debt / equity
0,08×
This company
0,62×
Market median
This company
Market median
87% below market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on Beactica Therapeutics AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
